Decrease in Operating Expenses
Operating expenses totaled $5.3 million for Q3 2024, down from $6 million in Q3 2023, representing a decrease of $0.6 million or 10.5%.
Reduction in R&D Expenses
Research and development expenses decreased by $0.8 million or 24.8%, primarily due to reduced clinical research organization expenses and lower equity expense.
Orphan Drug Designation for Certepetide
Certepetide was granted orphan drug designation by the U.S. FDA for the treatment of cholangiocarcinoma.
Strong Cash Position
As of September 30, 2024, Lisata had cash, cash equivalents, and marketable securities of approximately $35.9 million.
ASCEND Trial Progress
The ASCEND trial in metastatic pancreatic ductal adenocarcinoma reached a predetermined number of events, and an abstract was accepted for presentation at ASCO GI in January 2025.
BOLSTER Trial Enrollment Success
First-line cholangiocarcinoma cohort completed enrollment nearly 6 months ahead of schedule.